MENU
Aim higher

DeLiver

Targeted Treatment of Portal Hypertension in EVH Liver Patients

DeLiver aims to develop the first targeted treatment for liver patients prone to die from massive bleeding caused by Portal Hypertension (PH). The approach consists of delivering an effective amount of a kinase inhibitor to hepatic stellate cells (HSC) using the proprietary Lx linker and HSC specific nanobodies (called LxL1). DeLiver is a pre-clinical study permitting assessment of LxL1 in a first-in-man (FIM) investigator initiated trial (IIT) for a yet unmet medical condition
Acronym: 
DeLiver
Project ID: 
10 844
Ranking: 
64
Cut-off: 
6
Start date: 
01-04-2017
Project Duration: 
36months
Project costs: 
2 715 670.00€
Technological Area: 
Pharmaceutical Products / Drugs
Market Area: 
Therapeutic